Exhibit 99.1
 vandaq32019earningsca_imag.jpg
Vanda Pharmaceuticals Reports Second Quarter 2021 Financial Results
 
•Q2 2021 total revenues were $67.9 million, a 9% increase compared to Q2 2020
•Total revenues for the first six months of 2021 were $130.6 million, a 9% increase compared to the first six months of 2020
•Results from Phase III clinical study of tradipitant in gastroparesis are expected by the end of 2021
WASHINGTON – July 28, 2021 /PRNewswire/ – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2021.
“Vanda had another outstanding quarter of commercial revenue growth as we resumed activity across a number of our clinical programs. Our tradipitant in gastroparesis program is nearing completion, bringing us closer to a much-needed new treatment option for patients with gastroparesis and a potentially transformational commercial opportunity for Vanda,” said Mihael H. Polymeropoulos, M.D., Vanda’s President, CEO and Chairman of the Board.
Financial Highlights
Second Quarter of 2021
 
•Total net product sales from HETLIOZ® and Fanapt® were $67.9 million in the second quarter of 2021, a 9% increase compared to $62.2 million in the second quarter of 2020.
 
•HETLIOZ® net product sales were $44.5 million in the second quarter of 2021, a 7% increase compared to $41.6 million in the second quarter of 2020.

•Fanapt® net product sales were $23.4 million in the second quarter of 2021, a 13% increase compared to $20.6 million in the second quarter of 2020.

•Income before taxes was $12.6 million in the second quarter of 2021 compared to $11.1 million in the second quarter of 2020.
First Six Months of 2021

•Total net product sales from HETLIOZ® and Fanapt® were $130.6 million in the first six months of 2021, a 9% increase compared to $120.2 million in the first six months of 2020.
 
•HETLIOZ® net product sales were $83.9 million in the first six months of 2021, a 9% increase compared to $76.9 million in the first six months of 2020.

•Fanapt® net product sales were $46.7 million in the first six months of 2021, an 8% increase compared to $43.3 million in the first six months of 2020.

•Income before taxes was $23.0 million in the first six months of 2021 compared to $12.3 million in the first six months of 2020.

•Cash, cash equivalents and marketable securities (Cash) was $396.5 million as of June 30, 2021, representing an increase to Cash of $56.6 million compared to June 30, 2020.


Key Operational Highlights
Tradipitant
•The Phase III clinical study of tradipitant in gastroparesis is nearing completion with 95% of the target 200 patients already enrolled. Results are expected by the end of 2021.
HETLIOZ® (tasimelteon)
•A Phase III clinical study of HETLIOZ® in delayed sleep phase disorder (DSPD) is currently enrolling patients.
Fanapt® (iloperidone)
•A Phase III clinical study of Fanapt® in bipolar disorder is currently enrolling patients.A clinical pharmacology study of the long acting injectable (LAI) formulation of Fanapt® is ongoing.
Key Publications
•The article “Tasimelteon safely and effectively improves sleep in Smith–Magenis syndrome: a double-blind randomized trial followed by an open-label extension” was published in July 2021 in Genetics in Medicine.1
GAAP Financial Results
Income before taxes was $12.6 million in the second quarter of 2021 compared to $11.1 million in the second quarter of 2020. Net income was $9.7 million in the second quarter of 2021 compared to net income of $8.7 million in the second quarter of 2020. Diluted net income per share was $0.17 in the second quarter of 2021 compared to diluted net income per share of $0.16 in the second quarter of 2020.
Income before taxes was $23.0 million in the first six months of 2021 compared to $12.3 million in the first six months of 2020. Net income was $18.3 million in the first six months of 2021 compared to net income of $9.2 million in the first six months of 2020. Diluted net income per share was $0.32 in the first six months of 2021 compared to diluted net income per share of $0.17 in the first six months of 2020.
2021 Financial Guidance
Vanda expects to achieve the following financial objectives in 2021:

Full Year 2021
Financial Objectives
Full Year 2021
Guidance
Total revenues$270 to $300 million
HETLIOZ® net product sales
$180 to $200 million
Fanapt® net product sales
$90 to $100 million
Year-end 2021 CashGreater than $400 million

Conference Call
Vanda has scheduled a conference call for today, Wednesday, July 28, 2021, at 4:30 PM ET. During the call, Vanda’s management will discuss the second quarter 2021 financial results and other corporate activities. Investors can call 1-866-688-9426 (domestic) or 1-409-216-0816 (international) and use passcode 5298904. A replay of the call will be available on Wednesday, July 28, 2021, beginning at 7:30 PM ET and will be accessible until Wednesday, August 4, 2021 at 7:30 PM ET. The replay call-in number is 1-855-859-2056 for domestic callers and 1-404-537-3406 for international callers. The passcode number is 5298904.
The conference call will be broadcast simultaneously on Vanda’s website, www.vandapharma.com. Investors should click on the Investors tab and are advised to go to the website at least 15 minutes early to register, download, and install any necessary software or presentations. The call will also be archived on Vanda’s website for a period of 30 days.


References
1.Polymeropoulos, C.M., Brooks, J., Czeisler, E.L., Fisher, M.A., Gibson, M.M., Kite, K., Smieszek, S.P., Xiao, C., Elsea, S.H., Birznieks, G., Polymeropoulos, M.H. (2021). Tasimelteon safely and effectively improves sleep in Smith–Magenis syndrome: a double-blind randomized trial followed by an open-label extension. Genetics in Medicine. https://doi.org/10.1038/s41436-021-01282-y
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter @vandapharma.
CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS
Various statements in this press release, including, but not limited to, the guidance provided under “2021 Financial Guidance” above and statements regarding the clinical development and regulatory timelines and commercial potential for tradipitant are “forward-looking statements” under the securities laws. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda’s forward-looking statements include, among others, Vanda’s assumptions regarding its ability to continue to grow its business in the U.S., Vanda’s ability to complete the clinical development and obtain regulatory approval for tradipitant in the treatment of gastroparesis, the prevalence of gastroparesis and Vanda’s ability to successfully commercialize tradipitant. Therefore, no assurance can be given that the results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda’s business and market, particularly those identified in the “Cautionary Note Regarding Forward-Looking Statements”, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Vanda’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as updated by Vanda’s subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.
All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.


VANDA PHARMACEUTICALS INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except for share and per share amounts)
(unaudited)
 
 Three Months EndedSix Months Ended
 June 30
2021		June 30
2020		June 30
2021		June 30
2020
Revenues:
HETLIOZ® net product sales
$44,509 $41,561 $83,852 $76,897 
Fanapt® net product sales
23,390 20,646 46,716 43,310 
Total revenues67,899 62,207 130,568 120,207 
Operating expenses:
Cost of goods sold excluding amortization6,566 5,847 12,596 11,054 
Research and development20,248 12,903 36,379 28,430 
Selling, general and administrative28,347 33,917 58,144 70,938 
Intangible asset amortization369 369 739 739 
Total operating expenses55,530 53,036 107,858 111,161 
Income from operations12,369 9,171 22,710 9,046 
Other income235 1,918 322 3,284 
Income before income taxes12,604 11,089 23,032 12,330 
Provision for income taxes2,951 2,375 4,729 3,130 
Net income$9,653 $8,714 $18,303 $9,200 

Net income per share, basic		$0.17 $0.16 $0.33 $0.17 
Net income per share, diluted$0.17 $0.16 $0.32 $0.17 

Weighted average shares outstanding, basic		55,582,916 54,501,308 55,365,558 54,153,812 
Weighted average shares outstanding, diluted56,903,340 55,081,397 56,705,419 54,975,771 


VANDA PHARMACEUTICALS INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)
 
June 30
2021		December 31
2020
ASSETS
Current assets:
Cash and cash equivalents$57,242 $61,031 
Marketable securities339,251 306,709 
Accounts receivable, net37,090 30,036 
Inventory1,055 1,280 
Prepaid expenses and other current assets12,014 10,089 
Total current assets446,652 409,145 
Property and equipment, net3,631 4,136 
Operating lease right-of-use assets9,898 10,459 
Intangible assets, net20,820 21,559 
Deferred tax assets78,641 81,516 
Non-current inventory and other8,003 6,641 
Total assets$567,645 $533,456 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued liabilities$31,788 $31,509 
Product revenue allowances40,201 34,427 
Total current liabilities71,989 65,936 
Operating lease non-current liabilities10,740 11,497 
Other non-current liabilities3,696 2,757 
Total liabilities86,425 80,190 
Stockholders’ equity:
Common stock56 55 
Additional paid-in capital
660,086 650,300 
Accumulated other comprehensive income103 239 
Accumulated deficit(179,025)(197,328)
Total stockholders’ equity481,220 453,266 
Total liabilities and stockholders’ equity$567,645 $533,456 



Corporate Contact:

AJ Jones II
Chief Corporate Affairs and Communications Officer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com

Elizabeth Van Every
Head of Corporate Affairs
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
SOURCE Vanda Pharmaceuticals Inc.